Antiviral Treatment on Pregnancy with COVID-19 Infection : A Systematic Review

Simanjuntak, Tigor Peniel and Kakerissa, Angela Putri and Kurniawan, Grady Ivan (2021) Antiviral Treatment on Pregnancy with COVID-19 Infection : A Systematic Review. Indonesian Journal of Obstetrics & Gynecology Science. ISSN 2615 496X

	Text AntiviralTreatmentOnPregnancy.pdf Download (866kB)
	Text (Hasil_Turnitin) HasilTurnitinAntiviralTreatmentonPregnancy.pdf Download (2MB)

Abstract

Tujuan untuk mengevaluasi penggunaan obat antivirus, lama pengobatan, dan efek samping pada wanita hamil dengan infeksi COVID-19 berdasarkan usia kehamilan dan derajat keparahan. Metode tinjauan literatur sistematis tentang penggunaan obat antivirus, lama pengobatan, dan efek samping pada wanita hamil dengan infeksi COVID-19 berdasarkan usia kehamilan dan tingkat keparahan. Tinjauan sistematis mengikuti pedoman dari Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Hasil terdapat 948 jurnal yang diakses melalui Pubmed, Scopus, Science Direct, Cohcrane dan lainya dengan kata kunci : Antiviral, Pregnancy, Pregnant, Coronavirus, COVID-19, SARS-CoV-2. Terdapat jurnal yang terduplikasi (n=302), topik dan abstrak yang tidak sesuai kriteria (n=612), dan 25 jurnal yang tidak sesuai kriteria inklusi. Terdapat 9 jurnal yang memenuhi kriteria inklusi (laporan kasus dan studi retrosepktif kohort) yang membahas 20 wanita hamil dengan infeksi COVID-19 (16 kasus dengan derajat sedang dan berat menerima Remdesivir, 3 kasus derajat sedang dan ringan menerima kombinasi Lopinavir-ritonavir, dan 1 kasus derajat sedang menerima Arbidol). Kesimpulan, remdesivir adalah antivirus yang sering digunakan pada wanita hamil trisemester II dan III dengan infeksi COVID-19 derajat berat, lama pengobatan 5-10 hari. Remdesivir harus diwaspadai karena dapat menimbulkan efek samping seperti peningkatan fungsi hati. Kata kunci: Antivirus, Hamil, COVID-19 / Objective to evaluate antiviral treatment, duration, and side effects on pregnant women based on gestational age and severity of COVID-19 infection. Method: a systematic review of antiviral treatment, duration, and side effects on pregnant women based on gestational age and severity of COVID-19 infection. Systematic review was conducted following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) Statement. Result 948 papers accessed through Pubmed, Scopus, Science Direct, Cohcrane, and other with keywords “Antiviral”, “Pregnancy” “Pregnant” “Coronavirus” “COVID-19” “SARS-CoV-2”. Duplicate papers were excluded (n=302), topics and abstracts that do not meet the criteria (n=612), and 25 papers that did not meet the inclusion criteria. 9 papers that meet the inclusion criteria (case reports and cohort retrospective case study) discussed 20 pregnant women with COVID-19 infection (16 moderate and severe cases received Remdesivir, 3 moderate and mild cases received Lopinavir-ritonavir combination, and 1 moderate case received Arbidol). Conclusion, remdesivir is an antiviral frequently used in pregnancy on trimester II and III with severe COVID-19 infection with a duration of treatment of 5-10 days. Remdesivir should be monitored because some show side effects of increasing liver function. Key word: Antiviral, Pregnant, COVID-19

Actions (login required)

View Item